TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01776320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
Study: NCT03087890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cotrimoxazole
Description: Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2 tablets placebo daily for 48 weeks
Study: NCT01187368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVAHEART Left Ventricular Assist System (LVAS)
Description: Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate 3
Description: Three-hundred and ninety-nine (399) subjects will be enrolled and randomized in a 2:1 assignment to receive EVA2 or the comparator device, HeartMate 3.
Study: NCT02578680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline solution
Description: IV infusion
Study: NCT02879591

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Social Skills training with Avatar therapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Skills training with Avatar therapist
Study: NCT03300817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 Peptide-Poly-ICLC Vaccine
Description: Given SC
Study: NCT03290417

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 5000 IU/cap; One cap by mouth daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 720 mg/cap; one capsule by mouth 3 times per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: 250mg/cap; two capsules by mouth 4 times per day
Study: NCT04494347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MitraClip TMVR and Watchman LAAO
Description: The MitraClip device is a percutaneous edge-to-edge repair device that is intended to approximate the anterior and posterior mitral valve leaflets in patients with severe symptomatic mitral regurgitation with suitable anatomy. Device versions/types: MitraClip NTr, MitraClip XTr. The WATCHMAN device is a self-expanding left atrial appendage occlusion (LAAO) device with a porous covering on the proximal face. Device sizes: 21 mm, 24 mm, 27 mm, 30 mm, 33 mm.
Study: NCT00697866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 3 consecutive lots; 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 3 consecutive lots; 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 3 consecutive lots; 3-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study: NCT00549900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
Description: Intramuscular injection, 3 doses
Study: NCT02918396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scar-Based Radio-frequency Ablation
Description: Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (\>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as \<0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotor Anchors Radio-frequency Ablation
Description: Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PVI by Radio-frequency Ablation
Description: Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
Study: NCT04015609

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaning Centered Psychotherapy for Latinos
Description: MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy for Latinos
Description: MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
Description: Determines the degree of spiritual well-being

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
Description: Determines the degree of spiritual well-being

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
Description: Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
Description: Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-assessment questionnaire
Description: Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-assessment questionnaire
Description: Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
Study: NCT03047356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: If-then plans
Description: If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: If-then plans
Description: If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
Study: NCT04177485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS text reminders
Description: SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
Study: NCT03812653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
Study: NCT03762018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
Study: NCT00925912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perianal block
Description: 0.25% bupivacaine injected at perianal region
Study: NCT03762018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
Study: NCT00727181

Intervention type: DEVICE
Group type: OTHER
Intervention: Trifecta aortic heart valve
Description: Replacement of a diseased, damaged, or malfunctioning aortic heart valve
Study: NCT00195403

Intervention type: DRUG
Intervention: Etanercept
Description: Etanercept 25mg Injection, 2 times/week
Study: NCT00686465

Intervention type: OTHER
Group type: OTHER
Intervention: PET/CT scan
Description: Patients will undergo whole body FDG-PET/CT imaging
Study: NCT04449952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint
Description: Participants use 20 mL of Listerine cool mint mouth rinse for 30 sec after brushing
Study: NCT00166114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desipramine
Description: 25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
Study: NCT00460408

Intervention type: DRUG
Intervention: Macugen
Description: Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
Study: NCT04449952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% Hydroalcohol Mouth Rinse
Description: Participants use 20 mL of 5% Hydroalcohol mouth rinse for 30 sec after brushing.
Study: NCT02683174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel ambulatory patch (ZIO® XT Patch)
Description: All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNP and hs-troponin I at 0 and 3 hours post ED attendance
Description: All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
Study: NCT04574206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elaborative Reminiscence (ER)
Description: Parents will be trained to use elaborative communication techniques in conversations with their child.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Present Tense Talk (PTT)
Description: Parents will be trained to engage their children in conversations, describing activities as they are actually happening.
Study: NCT00123409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone disease management
Description: Telephone based care management

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care
Study: NCT02705976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
Study: NCT02930317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (50 IU/kg)
Study: NCT03762018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
Study: NCT02930317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (On-demand treatment)
Study: NCT01824225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Study: NCT03944200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229_01(A), Sugamet SR Tab 5/1000mg®
Description: Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)
Description: Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
Study: NCT02798653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choriomon® injection
Description: Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choriomon® injection+Endometrin ®
Description: Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endometrin ® vaginal tablets
Description: Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
Study: NCT03098589

Intervention type: DRUG
Intervention: Revlimid
Description: Revlimid
Study: NCT00610558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 1: Juvenile Myoclonic Epilepsy
Description: Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 2: Frontal Lobe Epilepsy
Description: Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 3: Normal Controls
Description: Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
Study: NCT03770520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QFR-guided CABG
Description: CABG surgery based on CAG and QFR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided CABG
Description: CABG surgery based on heart team discussion of CAG
Study: NCT02895659

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)
Description: Perioperative hemodynamic management will be performed according to a specified treatment protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)
Description: Perioperative hemodynamic management will be performed according to a specified treatment protocol.
Study: NCT03762018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
Study: NCT02121392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Nerve Block Catheter
Description: ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Adductor Canal Nerve Block Sham Catheter
Description: Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.